Explore CD79b

CD79b, a component of the B-cell receptor (BCR), is expressed on over 90% of B-cell NHL malignancies.1-3

Our successful experiences with researching B-cell antigens, such as CD20, has led to exploration of additional B-cell surface proteins.3,4 CD79b, along with CD79a and a surface immunoglobulin, make up the BCR. CD79b, like CD20, is expressed on nearly all B-cell surfaces.1,2,5

CD79b: a B-cell surface antigen

CD79b can be internalized upon antibody binding.4,6 Due to this functionality, CD79b has the potential to selectively deliver molecules of interest to B cells found in non-Hodgkin lymphomas (NHLs) such as diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).4,5

CD79b-specific binding in B-cell malignancies

CD79b-specific binding in B-cell malignancies4

Exploiting CD79b internalization

In preclinical models, antibody binding to CD79b was shown to trigger the internalization of the BCR and bound antibody. This research established the potential for selective delivery of molecules of interest to B cells.4

Degrading the internalized antibody and BCR

Once internalized, the BCR complex and bound antibody are degraded, releasing the cytotoxic drug.4

References

Antibodies icon

Emerging development platforms

Discover our broad range of antitumor modalities.

Microscope icon

Discover cancer biomarkers

Learn more about the importance of cancer biomarkers.